ROSIGLITAZONE EFFCT ON ADIPCYTE-DERIVD CYTOKINES IN NONDIABTC PTS W/METABLC SYND

罗格列酮对非NDIABTC PTS W/METABLC SYND 中脂肪细胞衍生细胞因子的影响

• 批准号: 7377823
• 负责人: CHRISTINA L AQUILANTE
• 金额: $ 7.24万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377823
• 关键词: ROSIGLITAZONE; EFFCT; ADIPCYTE; DERIVD; CYTOKINES

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine if rosiglitazone, an 'insulin sensitizer', will favorably alter fat cell proteins in people with the metabolic syndrome. The metabolic syndrome is a collection of health risks that increase a person's chance for the future development of type 2 diabetes and cardiovascular disease. Because the metabolic syndrome is increasing at alarming rates in the United States, identification of alternative ways to alter disease progression in this population is essential. Rosiglitazone may be helpful in altering the amount of proteins made by the fat cells. This may improve the body's ability to use insulin and impact some of the parts of the metabolic syndrome. Currently, use of medications, like rosiglitazone, is not standard of care in people who have the metabolic syndrome. Our study is an early step to see if rosiglitazone will be beneficial in people who have the metabolic syndrome.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。本研究的目的是确定罗格列酮（一种“胰岛素增敏剂”）是否会有利地改变代谢综合征患者的脂肪细胞蛋白质。代谢综合征是一系列健康风险的集合，这些风险会增加一个人未来患 2 型糖尿病和心血管疾病的机会。由于代谢综合征在美国正以惊人的速度增加，因此寻找改变该人群疾病进展的替代方法至关重要。 罗格列酮可能有助于改变脂肪细胞产生的蛋白质的量。这可能会提高身体使用胰岛素的能力并影响代谢综合征的某些部分。目前，使用罗格列酮等药物并不是代谢综合征患者的标准治疗方法。我们的研究是了解罗格列酮是否对代谢综合征患者有益的早期研究。